Literature DB >> 15148250

Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries.

Saoirse E O'Sullivan1, David A Kendall, Michael D Randall.   

Abstract

1 In order to address mechanistic differences between arterial vessel types, we have compared the vasorelaxant actions of anandamide in resistance (G3) and conduit (G0) mesenteric arteries. 2 Anandamide produced concentration-dependent relaxations of pre-constricted G3 arteries with a maximal response that was significantly greater than seen in G0. 3 The CB1 receptor selective antagonists SR141716A (100 nm) and AM251 (100 nm) caused reductions in the vasorelaxant responses to anandamide in both arteries. Maximal vasorelaxant responses to anandamide were reduced in both arteries after treatment with capsaicin to deplete sensory neurotransmitters (10 microm for 1 h). 4 Vasorelaxation to anandamide was not affected by the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 300 microm) in either artery. Only responses in G3 arteries were sensitive to removal of the endothelium. In G3 vessels only, vasorelaxation to anandamide was reduced by inhibition of EDHF activity with a combination of charybdotoxin (100 nm) and apamin (500 nm) in the presence of L-NAME (300 microm) and indomethacin (10 microm). 5 Antagonism of the novel endothelial cannabinoid receptor (O-1918, 1 microm) caused a reduction in the sensitivity to anandamide in G3 but not G0. 6 G3, but not G0, vessels showed a small reduction in vasorelaxant responses to anandamide after inhibition of gap junctional communication with 18alpha-GA (100 microm). 7 These results demonstrate that there are differences in the mechanisms of vasorelaxation to anandamide between conduit and resistance mesenteric arteries. In small resistance vessels, vasorelaxation occurs through stimulation of vanilloid receptors, CB1 receptors, and an endothelial receptor coupled to EDHF release. By contrast, in the larger mesenteric artery, vasorelaxation is almost entirely due to stimulation of vanilloid receptors and CB1 receptors, and is endothelium-independent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15148250      PMCID: PMC1574972          DOI: 10.1038/sj.bjp.0705810

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism.

Authors:  L De Petrocellis; T Bisogno; M Maccarrone; J B Davis; A Finazzi-Agro; V Di Marzo
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

2.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Authors:  Z Járai; J A Wagner; K Varga; K D Lake; D R Compton; B R Martin; A M Zimmer; T I Bonner; N E Buckley; E Mezey; R K Razdan; A Zimmer; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries.

Authors:  V Ralevic; D A Kendall; M D Randall; P M Zygmunt; P Movahed; E D Högestätt
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication.

Authors:  A T Chaytor; P E Martin; W H Evans; M D Randall; T M Griffith
Journal:  J Physiol       Date:  1999-10-15       Impact factor: 5.182

5.  Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.

Authors:  László Offertáler; Fong-Ming Mo; Sándor Bátkai; Jie Liu; Malcolm Begg; Raj K Razdan; Billy R Martin; Richard D Bukoski; George Kunos
Journal:  Mol Pharmacol       Date:  2003-03       Impact factor: 4.436

6.  Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.

Authors:  R White; W S Ho; F E Bottrill; W R Ford; C R Hiley
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

7.  Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries.

Authors:  B Vanheel; J Van de Voorde
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

8.  Endothelium-independent relaxation to cannabinoids in rat-isolated mesenteric artery and role of Ca2+ influx.

Authors:  W-S Vanessa Ho; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

9.  Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA).

Authors:  Saoirse E O'Sullivan; David A Kendall; Michael D Randall
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

10.  G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current.

Authors:  Malcolm Begg; Fong-Ming Mo; László Offertaler; Sándor Bátkai; Pál Pacher; Raj K Razdan; David M Lovinger; George Kunos
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

View more
  25 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

2.  GPR55 and the vascular receptors for cannabinoids.

Authors:  C R Hiley; S S Kaup
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

3.  Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product.

Authors:  H Kozłowska; M Baranowska; E Schlicker; M Kozłowski; J Laudañski; B Malinowska
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

4.  Vasorelaxation to N-oleoylethanolamine in rat isolated arteries: mechanisms of action and modulation via cyclooxygenase activity.

Authors:  A J Wheal; S P H Alexander; M D Randall
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide.

Authors:  Saoirse E O'Sullivan; David A Kendall; Michael D Randall
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 8.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

9.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

10.  Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats.

Authors:  A J Wheal; T Bennett; M D Randall; S M Gardiner
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.